Levodopa: Effect on cell death and the natural history of Parkinson's disease

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 37-44

  Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Levodopa; Oxidative stress; Parkinson's disease

Indexed keywords

LEVODOPA; REACTIVE OXYGEN METABOLITE; ANTIPARKINSON AGENT;

AEROBIC METABOLISM; CELL DEATH; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EPIDEMIOLOGICAL DATA; HUMAN; NERVE CELL CULTURE; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TYPES OF STUDY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IN VITRO STUDY; PATHOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; CELL DEATH; CLINICAL TRIALS AS TOPIC; HUMANS; IN VITRO TECHNIQUES; LEVODOPA; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84920870768     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26119     Document Type: Review

References (65)

1. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.
2. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
3. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
4. Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect 1989;1:279-295.
5. Dexter DT, Wells FR, Agid F, Lees AJ, Jenner P, Marsden CD. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987;2:1219-1220.
6. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
7. Spencer JP, Jenner P, Daniel SE, et al. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998; 71:2112-2122.
8. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
9. Yoritaka A, Hatton N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996;93:2696-2701.
10. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203.
11. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47(Suppl 3):161-170.
12. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-1349.
13. Rochet JC, Outeiro TF, Conway KA, et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 2004;23:23-34.
14. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-788.
15. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 1995;64:825-832.
16. Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997;12:17-23.
17. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
18. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993;61:1470-1478.
19. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66:501-510.
20. Pardo B, Mena MA, Fahn S, García de Yébenes J. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
21. Kalir HH, Mytilineou C. Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development. J Neurochem 1991;57:458-464.
22. Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16:2553-2562.
23. Mena MA, Casarejos MJ, Carazo A, Paino CL, García de Yébenes J. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997;104:317-328.
24. Tallaksen CM, Bohmer T, Bell H. Concentrations of the water-soluble vitamins thiamin, ascorbic acid, and folic acid in serum and cerebrospinal fluid of healthy individuals. Am J Clin Nutr 1992;56:559-564.
25. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
26. Perry TL, Yong VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43:990-993.
27. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
28. Lyras L, Zeng BY, McKenzie G, et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002;109:53-67.
29. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
30. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001;16:424-434.
31. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. J Neural Transm 2001;108:925-941.
32. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharm Exp Ther 2003;304:792-800.
33. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
34. Nair VD, Olanow CW. Differential modulation of Akt/GSK-3β pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem 2008;283:15469-15478.
35. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161-S170.
36. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
37. Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77:1420-1426.
38. Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease. Still a need for equipoise. Neurology 2011;77:1416-1417.
39. Diamond SG, Markham CH. Longitudinal study of effects of early levodopa treatment on disability and mortality in Parkinson's disease. Adv Neurol 1990;53:399-403.
40. Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384:1196-1205.
41. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
42. Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET Study: Ann Neurol 2003;54:93-101.
43. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
44. Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Eng J Med 2004;351:2498-2508.
45. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000;15:485-489.
46. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002;17:961-968.
47. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
48. Olanow CW, Kieburtz K, Rascol O, et al.; for the STRIDE-PD investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.
49. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in the treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
50. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265.
51. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
52. Olanow CW, Kieburtz K, Odin P, et al. Double-blind, double-dummy study of continuous intrajejunal delivery of levodopa/carbidopa intestinal gel in advanced Parkinson's disease. Lancet Neurol 2014;13:141-149.
53. Bertoni JM, Arlette JP, Fernandez HH, et al.; North American Parkinson's and Melanoma Survey Investigators. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010;67:347-352.
54. Vermeij JD, Winogrodzka A, Trip J, Weber WE. Parkinson's disease, levodopa-use and the risk of melanoma. Parkinsonism Relat Disord 2009;15:551-553.
55. Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord 2013;28:1391-1397.
56. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
57. Nobrega F, Glattre E, Kurland LT, et al. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JR, eds. Progress in Neurogenetics. Amsterdam: Excerpta Medica; 1967:474-485.
58. Rajput AH, Uitti RJ, Rajput AH, et al. Timely levodopa prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997;3:159-165.
59. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clinics 1996;14:317-335.
60. Marttila RJ, Rinne KU. Progression and survival in Parkinson's disease. Acta Neurol Scand 1991;84:24-28.
61. Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926.
62. Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1615-1622.
63. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999;14:911-913.
64. Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet 2002;360:575.
65. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.